Propeller Health announced today it has partnered with Novartis Pharma AG to develop a custom add-on sensor for the Breezhaler inhaler to further improve adherence and care management for people living with COPD and asthma.

“We’re excited to work with the team at Novartis to connect the Breezhaler device to the Propeller platform,” Propeller Health CEO David Van Sickle said in a statement. “The addition of this major respiratory franchise represents an important next step in our mission to bring valuable digital companions to everyone’s respiratory treatments.”

According to a release, the new custom sensors in the Breezhaler inhaler will allow for passively recording and transmitting compliance data, better informing patients and their physicians of adherence and other treatment factors through the Propeller platform.

The partnership will be focused on COPD in Europe.